Earnings Feed
Start Free
Home/Filings/4/0001104659-18-074357
4//SEC Filing

Leamon Christopher P 4

Accession 0001104659-18-074357

CIK 0001235007other
View on SEC.govCompany Profile

Filed

Dec 20, 7:00 PM ET

Accepted

Dec 21, 12:53 PM ET

Size

33.6 KB

Accession

0001104659-18-074357

Insider Transaction Report

Form 4
Period: 2018-12-21
ENDOCYTE INCECYT
Leamon Christopher P
Vice President of Research
Transactions
  • Disposition to Issuer

    Common Stock

    2018-12-21$24.00/sh−4,375$105,000→ 0 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2018-12-21$14.14/sh−70,000$989,800→ 0 total
    Exercise: $9.86Exp: 2023-02-19→ Common Stock (70,000 underlying)
  • Disposition to Issuer

    Common Stock

    2018-12-21$24.00/sh−164,256$3,942,144→ 0 total
  • Disposition to Issuer

    Common Stock

    2018-12-21$24.00/sh−13,125$315,000→ 0 total
  • Disposition to Issuer

    Common Stock

    2018-12-21$24.00/sh−20,000$480,000→ 0 total
  • Disposition to Issuer

    Common Stock

    2018-12-21$24.00/sh−22,500$540,000→ 0 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2018-12-21$14.95/sh−27,500$411,125→ 0 total
    Exercise: $9.05Exp: 2021-04-14→ Common Stock (27,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2018-12-21$20.45/sh−59,996$1,226,918→ 0 total
    Exercise: $3.55Exp: 2022-02-28→ Common Stock (59,996 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2018-12-21$20.82/sh−52,498$1,093,008→ 0 total
    Exercise: $3.18Exp: 2026-02-04→ Common Stock (52,498 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2018-12-21$21.84/sh−35,000$764,400→ 0 total
    Exercise: $2.16Exp: 2027-02-02→ Common Stock (35,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2018-12-21$12.89/sh−45,000$580,050→ 0 total
    Exercise: $11.11Exp: 2024-02-06→ Common Stock (45,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2018-12-21$18.90/sh−52,498$992,212→ 0 total
    Exercise: $5.10Exp: 2025-02-04→ Common Stock (52,498 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2018-12-21$20.99/sh−45,000$944,550→ 0 total
    Exercise: $3.01Exp: 2028-02-08→ Common Stock (45,000 underlying)
Footnotes (9)
  • [F1]Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
  • [F2]This restricted stock unit ("RSU") award, which originally consisted of 8,750 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
  • [F3]This RSU award, which originally consisted of 17,500 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
  • [F4]This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
  • [F5]This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
  • [F6]This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
  • [F7]This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
  • [F8]This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
  • [F9]This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Documents

1 file

Issuer

ENDOCYTE INC

CIK 0001235007

→
Entity typeother

Related Parties

1
  • filerCIK 0001509415

Filing Metadata

Form type
4
Filed
Dec 20, 7:00 PM ET
Accepted
Dec 21, 12:53 PM ET
Size
33.6 KB
View on SEC.gov